B. Riley Securities Rates ClearPoint Neuro (CLPT) buy

B. Riley Securities maintains its buy rating on CLPT, setting a price target of $30, a 78.47% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 2:01 PM EDT · Updated Jun 19, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B. Riley Securities rated ClearPoint Neuro, Inc. ($CLPT) "buy" with a $30 price target on June 18, 2026.

Since the rating, $CLPT is up 1.1% after 1 week, down 15.3% after 1 month and down 49.0% to date (from the $17.77 close on Jun 18, 2026).

CLPT ClearPoint Neuro, Inc.

$9.07 -35.35% year to date

Daily close · Oct 16, 2026

Key Points

B. Riley Securities reiterated its buy rating on CLPT, setting a $30 price target on June 18, 2026.
B. Riley Securities's $30 price target implies 78.47% upside from ClearPoint Neuro, Inc.'s ($CLPT) current $16.81 share price.
CLPT shares are trading at $16.81, with notable insider buying activity in recent months.
Institutional investors like BlackRock and Geode Capital have adjusted their positions in CLPT.

Get $CLPT trade alerts by text

We text you when insiders, Congress or big funds trade $CLPT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ClearPoint Neuro, Inc. alert may contain errors. Disclosures

On June 18, 2026, B. Riley Securities reiterated its buy rating for CLPT, setting a price target of $30. Shares of CLPT are currently trading at $16.81, reflecting the firm's continued confidence in the company's potential.

Analysts Set New Price Targets

On June 18, 2026, B. Riley Securities maintained its buy rating on CLPT, with analyst Anderson Schock setting a price target of $30. This follows a series of buy ratings from B. Riley Securities, which previously set targets of $20 and $18 earlier in the year. The consistent buy ratings highlight the firm's bullish outlook on CLPT's future performance.

Other Institutional Activity in CLPT

Several institutional investors have been active in CLPT recently. BlackRock, Inc. increased its holdings by 39,117 shares, bringing its total to 2,082,750 shares valued at approximately $18.95 million. Geode Capital Management, LLC also added 51,375 shares, ending with 705,720 shares worth about $6.42 million. Meanwhile, Lane Generational LLC made a substantial increase, adding 146,242 shares to its portfolio, resulting in a total of 486,849 shares valued at $4.43 million.

Insider Buying and Selling at ClearPoint Neuro, Inc.

Insider activity at CLPT has been notable. On June 4, 2026, Timothy Richards sold 500 shares at $10 each and bought 500 shares on the same day. Additionally, he sold 376 shares at $13.30 and 5,415 shares at $12.17 earlier in June. Meanwhile, Linda Liau and John Fletcher each purchased 12,820 shares at no cost on May 21, 2026, indicating a strategic interest in the company's stock.

Bottom Line

B. Riley Securities' reiteration of its buy rating for CLPT with a $30 price target suggests confidence in the company's prospects. The stock is trading at $16.81, and recent insider buying activity and institutional adjustments highlight ongoing interest in CLPT. Investors often track these ratings and activities to gauge market sentiment, though it's important to remember that analyst ratings are forward-looking estimates.

12-month forecast